Latest Commercialisation Strategies News

Cleo Diagnostics has laid out a clear U.S. reimbursement pathway for its ovarian cancer test, leveraging an existing CPT code to enable early market entry and data collection ahead of FDA clearance.

Bayan Mining and US Critical Materials have signed a non-binding MoU to develop rare-earth processing technologies licensed from the Colorado School of Mines, targeting high-grade mineralisation at the Sheep Creek Project in Montana. The collaboration aims to support a US-based rare earth supply chain with potential strategic investment on the horizon.

Nexsen has secured a strategic partnership with GHK Hospital Limited in Hong Kong, marking a significant step in validating and commercialising its rapid point-of-care diagnostics across North Asia.

Forte Energy has rapidly expanded its oil and gas exploration portfolio in Alaska’s National Petroleum Reserve, acquiring over 156,000 acres including the billion-barrel Harrier Prospect and adjacent leases to Umiat Oil Field, while securing significant cost savings through lease fee suspensions.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

xReality Group delivered a standout Q3 FY26 with a 62% jump in cash receipts and a new Mixed Reality sale to the US Department of Defense, underpinning its growing Operator XR platform.

Epiminder has ramped up enrolment in its DETECT study, contracting 18 US medical centres and maintaining a robust $83.8 million cash position to fund its Minder device commercialisation through 2028.

Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.

InFocus Group Holdings has launched Codexa, a proprietary sweepstakes casino platform targeting the US market, and secured an expanded contract for its Prodigy9 subsidiary in Thailand, while navigating cash flow pressures amid ongoing R&D investment.

Dreadnought Resources has obtained regulatory approval for open pit mining at its Star of Mangaroon gold project in Western Australia, advancing its strategy to become a self-funded explorer by outsourcing development and processing.

Green360 Technologies has produced its first commercial batch of Eco-Clay under a tolling deal with Calix, advancing its low-carbon cement alternative towards market entry in Victoria by mid-2026.